Pharmacoeconomic analysis of Cellex® in the treatment of ischemic stroke

Actuality. Acute cerebral circulation disordersremain an important problem of modern health care. Available evidence suggests that both reperfusion and neuroprotection are important to ensure a favorable outcome of treatment. In the context of neuroprotection, considerable interest are peptideswith neuroprotective properties. A recent randomized controlled trial of the Cellex® showed positive results for treatment of severe patients with acute cerebral circulation disorders with less favorable outcomes and the highest direct medical costs, which makes the question of assessing the pharmacoeconomic properties of this drug relevant in the light of new data. Objective. To conduct a clinical and economic analysis of treatment outcomes for Cellex® and therapeutic alternatives used in patients with Acute cerebral circulation disorders and early rehabilitation period of the disease within the framework of the state guarantee programs of free medical care. Methodology. Pharmacoeconomic modeling, cost-e’ectiveness analysis, budget impact analysis. Results. Established that the use of Cellex® in the context of Russian practice in patients corresponding to the characteristics of the target population of this pharmacoeconomic study leads to reduce the budget burden by 26 % for 1 year, reaching 46 % at 4 years. ‹e cost-e’ectiveness analysis indicates that Cellex® leads to greater e‘ciency in the use of health resources. ‹e sensitivity analysis conŒrms the stability of this result to a change in the market situation, expressed in an increase in the price of Cellex® preparation to 25 % inclusive. This indicates a high pharmacoeconomic feasibility of Cellex® in the context of therapy the ischemic form of acute cerebral circulation disorders in Russian Federation.

1. Belousov YuB., Komarova VP, Belousov DYu. Uchebnoe posobie "Osnovy farmakoekonomicheskih issledovanij"[Textbook "Fundamentals of Pharmacoeconomic Research"]. Moscow. 2000. Nacionalnyj fond sodejstviya nauchnym i klinicheskim issledovaniyam pri RGMU. (In Russ)

2. Belskaya GN, Pizova NV, Sokolov MA i dr. Vliyani enejroprotektivnoj terapii na techenie cerebralnogo insulta. [Influence of neuroprotective therapy on the course of cerebral stroke]. Medicinskij sovet. 2016;11:26–31. (In Russ)

3. Belskaya GN, CHuprina SE, Vorobev AA, Gorozha EN, Butorakina TL, Sokolov MA, Izmajlov IA. Kognitivnye narusheniya pri insulte vozmozhnosti medikamentoznoj korrekcii [Cognitive impairment in stroke: the possibility of drug correction]. ZHNIP im S.S. Korsakova. 2016;5:33–37. (In Russ)

4. Belskaya GN, Krylova LG, Sokolov MA, Izmajlov IA. Vozmozhnosti korrekcii rechevyh rasstrojstv v Ostrom periode ishemicheskogo insulta s pomoshchyu nejroprotektivnoj terapii. [Opportunities for correcting speech disorders in the acute period of ischemic stroke with the help of neuroprotective therapy] ZHNIP im SS Korsakova. Insult. 2015;9(2):60-63. (In Russ)

5. Vilenskij BS. Sovremennaya taktika borby s insultom[Modern tactics to combat stroke]. SPb.: Foliant – 2005.

6. Gosudarstvennyj reestr predelnyh otpusknyh cen [State register of maximum selling prices] Available at: http://grls.rosminzdrav.ru/pricelims.aspx.

7. Gusev EI. Problemainsulta v Rossii [The problem of stroke in Russia]. Zhurnal nevropatologii i psihiatr. (рrilozhenie. Insult). 2003;9:3–10. (In Russ)

8. Denisova EV. Aktualnye voprosy epidemiologii sosudistyh zabolevanij golovnogo mozga v mire. [Topical issues of the epidemiology of cerebrovascular diseases in the world]. Vestnik obshchestvennogo zdorovya i zdravoohraneniya Dalnego Vostoka Rossii. 2011;3:8–15. (In Russ)

9. Insult: diagnostika lechenie profilaktika. [Stroke: diagnosis, treatment, prevention] Pod red ZA Suslinoj, MA. Piradova. M.: MEDpress-inform, 2008 g. (In Russ)

10. Informacionnyj servis aptekamos.ru [Information service "aptekamos.ru"]. Available at: http://aptekamos.ru/

11. Kamchatnov PR, Chugunov AV. Metabolicheskaya terapiya v vedenii bolnogo ishemicheskim insultom. [Metabolic therapy in the management of patients with ischemic stroke]. Farmateka. 2014;9:33-38. (In Russ)

12. Kamchatnov PR, Izmajlov IA, UmarovaHYa i dr. Rezultaty primeneniya Celleksa u bolnyh ishemicheskim insultom. [Results of Cellex application in patients with ischemic stroke]. Farmateka. 2015;19:52–57. (In Russ)

13. Kotov SV, Stahovskaya LV, Isakova EV, Ivanova GE i dr. Insul't. Rukovodstvo dlya vrachej [Stroke. A guide for doctors]; pod red. LV Stahovskoj, SV Kotova. M.: MIA, 2013; 400. (In Russ)

14. Mel'nikova EV, Shmonin AA, Mal'ceva MN, Ivanova GE. Modificirovannaya shkala Rehnkina – universal'nyj instrument ocenki nezavisimosti i invalidizacii pacientov v medicinskoj reabilitacii [The modified Rankin scale is a universal tool for assessing the independence and disability of patients in medical rehabilitation]. ConsiliumMedicum. 2017;19 (2.1):8–13. (In Russ)

15. Metodicheskie rekomendacii FGBU "CEHKKMP" Minzdrava Rossii po ocenke vliyaniya na byudzhet v ramkah realizacii Programmy gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoschi [Methodical recommendations of FGBU "CEHKKMP" of the Ministry of Health of Russia to budget impact analysis as a part of the implementation of the State Program of guarantees for free provision of medical care to citizens]. Moscow: FGBU "CEHKKMP" MinzdravaRossii, 2016. Available at: https://rosmedex.ru/25-12-16/ (In Russ)

16. Metodicheskie rekomendacii FGBU "CEHKKMP" Minzdrava Rossii po provedeniyu sravnitel'noj kliniko-ehkonomicheskoj ocenki lekarstvennogo preparata [Methodical recommendations of FGBU "CEHKKMP" of the Ministry of Health of Russia for conducting a comparative clinical and economic evaluation of a medicinal product]. Moscow: FGBU "CEHKKMP" Minzdrava Rossii, 2016. Available at: https://rosmedex.ru/25-12-16/ (In Russ)

17. Otraslevoj standart "Kliniko-ehkonomicheskie issledovaniya. Obschie polozheniya" [Industry standard "Clinical and economic research. General provisions"] Prikaz Minzdrava RF ot 27.05.2002. No163 vmeste s OST 91500.14.0001- 2002. (In Russ)

18. Otchet o rezul'tatah klinicheskogo issledovaniya po protokolu No TSELIV-2013 "Dvojnoe slepoe placebo kontroliruemoe randomizirovannoe mul'ticentrovoe klinicheskoe issledovanie ehffektivnosti preparata Celleks v lechenii bol'nyh s ostrym narusheniem mozgovogo krovoobrascheniya po ishemicheskomu tipu. AO "Farm-Sintez". M. 2018 [Report on the results of the clinical trial according to the protocol No. TSEL-IV-2013 "Double-blind, placebo-controlled, randomized, multicenter clinical trial of the effectiveness of the Cellex preparation in the treatment of patients with acute cerebrovascular disorders by ischemic type. JSC "Farm Sintez" Moscow. 2018] (In Russ)

19. Postanovlenie Pravitel'stva Moskvy ot 23 dekabrya 2016 g. No 935-PP "O territorial'noj programme gosudarstvennyh garantij Besplatnogo okazaniya grazhdanam medicinskoj pomoschi v gorode Moskve na 2017 god i na planovyj period 2018 i 2019 godov" (vred. Postanovleniya Pravitel'stva Moskvy ot 11.07.2017 No 462-PP). ["On the territorial program of state guarantees for free medical assistance to Moscow citizens for 2017 and for the planning period 2018 and 2019"] (In Russ)

20. Postanovlenie Pravitel'stva Rossijskoj Federacii No 95 ot 20 fevralya 2006 g. No 95 (red. ot 24.01.2018) "O poryadke i usloviyah priznaniya lica invalidom".[On the procedure and conditions for the recognition of a person with a disability] (In Russ)

21. Postanovlenie Pravitel'stva RF ot 04.06.2007 No 343 (red. ot 02.06.2016) "Ob osuschestvlenii ezhemesyachnyh kompensacionnyh vyplat nerabotayuschim trudosposobnym licam, osuschestvlyayuschim uhod za invalidom I gruppy (za isklyucheniem invalidov s detstva I gruppy), a takzhe za prestarelymi, nuzhdayuschimsya po zaklyucheniyu lechebnogo uchrezhdeniya v postoyannom postoronnem uhode libo dostigshim vozrasta 80 let". [On the implementation of monthly compensatory payments to unemployed able-bodied persons caring for a disabled person of the 1st group (with the exception of invalids from the childhood of the I group), as well as for the elderly who need a permanent care facility or who have reached the age of 80 years] (In Russ)

22. Skvorcova VI. Ishemicheski jinsul't: patogenezishemii, terapevticheskie podhody. [Ischemic stroke: the pathogenesis of ischemia, therapeutic approaches.] Nevrologicheskij zhurnal. 2001;(3):4–6. (In Russ)

23. Standart specializirovannoj medicinskoj pomoschi pri infarkte mozga. [Standard of specialized medical care for cerebral infarction.] Utverzhdyonprikazom MZ RF No 1740n ot 29 dekabrya 2012. (In Russ)

24. Tanashyan MM, Domashenko MA. Novye vozmozhnosti nejroprotekcii vlechenii pacientov s ostrymi narusheniyami mozgovogo krovoobrascheniya. [New possibilities of neuroprotection in the treatment of patients with acute cerebral disorders.] Nervous diseases. 2016, 1: 16–21]. Nervnyebolezni. 2016;1:16–21. (In Russ)

25. Tarifnoe soglashenie na oplatumedicinskoj pomoschi, okazyvaemoj po territorial'noj programme obyazatel'nogo medicinskogo strahovaniya goroda Moskvyna 2018 god ot "29" dekabrya 2017 goda, s prilozheniyami, g. Moskva [Tariff agreement for the payment of medical assistance provided under the territorial program of compulsory medical insurance of Moscow in 2018 from "29" December 2017]. Available at: http://www.mgfoms.ru/strahovye-kompanii/tarifi. (In Russ)

26. Federal'nyj zakon "O gosudarstvennom pensionnom obespechenii v Rossijskoj Federacii" [Federal Law "On State Pensions in the Russian Federation"] ot 15.12.2001 No 166-FZ. (In Russ)

27. Federal'nyj zakon "O social'noj zaschite invalidov v Rossijskoj Federacii". ["On the social protection of disabled people in the Russian Federation"]. Оt 24 noyabrya 1995 g. No 181-FZ. (In Russ)

28. Habriev RU, Kulikov AYu, Arinina EE. Metodologicheskie osnovy farmakoehkonomicheskogo analiza. [Methodological bases of pharmacoeconomic analysis]. Moscow. 2011. (In Russ)

29. Yagudina RI, Kulikov AYu, Metelkin IA. Metodologiya analiza "zatratyehffektivnost" pri provedenii farmakoehkonomicheskih issledovanij. [Methodology of "cost-effectiveness" analysis in conducting pharmacoeconomic studies.] Farmakoehkonomika. Sovremennaya farmakoehkonomika i farmakoehpidemiologiya. 2012;4:3–8. (In Russ)

30. Yagudina RI, Chibilyaev VA. Ispol'zovanie konechnyh i surrogatnyh tochek v farmakoehkonomicheskih issledovaniyah. [Use of terminal and surrogate points in pharmacoeconomic studies]. Farmakoehkonomika. 2010;2:12–18. (In Russ)

31. Canadian Stroke Network: The quality of stroke care in Canada. 2011– Ottawa (ON) Available at: http://www.canadianstrokenetwork.ca/wp-content/ uploads/2011/06/QoSC-EN1.pdf

32. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120:439–448.

33. Guidelines for management of ischaemic stroke and transient ischaemic attack. European Stroke Organisation (ESO) Executive Committee. Cerebrovasc Dis. 2008;25:457–507.

34. Hutter-Paier B, Grygar E, Fruhwirth M, Temmel I, Windisch M. Further evidence that Cerebrolysin protects cortical neurons from neurodegeneration in vitro. J. Neural Transm. Suppl. 1998;53:363–72.

35. Kim AS, Johnston SC. Temporal and geographic trends in the global stroke epidemic. Stroke. 2013;44:123–125.

36. Kissela B, Lindsell CJ, Kleindorfer D, et al. Clinical Prediction of Functional Outcome after Ischemic Stroke: The Surprising Importance of Periventricular White Matter Disease and Race. Stroke; a journal of cerebral circulation. 2009;40(2):530–536.

37. Park JH, Ovbiagele B. Relationship of functional disability after a recent stroke with recurrent stroke risk. Eur J Neurol. 2016;23:361–367.

38. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49:e46.

39. Schwartz R. Biological Modeling and Simulation: A Survey of Practical Models, Algorithms and Numerical Methods. The MIT Press, 2008; Cambridge, Massachusetts, USA.

40. Yang CP, Finestone HM, Chen PY. Psychosocial determinants of longer length of stay on a Canadian stroke inpatient rehabilitation unit. Int J Phys Med Rehabil. 2015;3:281.